Oreon Life Science Co. Ltd.

What Oreon Life Science Co. Ltd. does

Oreon Life Science Co. Ltd. is a privately held South Korean medical aesthetics company founded in 2000 (originally as Orient Medical Group, restructured as Oreon Life Science in 2008) that develops, manufactures, and globally distributes a comprehensive portfolio of minimally invasive aesthetic products. Its core offerings include the Rainbow Thread lifting system built on PDO, PLLA, and PCLA biodegradable polymers; the AESSOA monophasic hyaluronic acid filler with lidocaine and proprietary Dap Dancing crosslinking technology; the re:on biphasic HA filler; the aesPlla PLLA collagen stimulator; the RE:ONNE mesotherapy solution with patented peptides and multi-growth factors; matching micro-cannula systems for each filler line; cosmeceutical mask packs; the reonox toxin product; and Lidocaine cream. The company operates manufacturing plants in Osong (since 2013) and Seongnam (since 2019), with a third plant under development at Wonju, and holds CE (Class III for threads), ISO 13485, ISO 9001, GMP, and Korean MFDS certifications.

The company sells exclusively through a network of regional distributors — one exclusive partner per territory — covering more than 70 countries across Europe, the CIS, Middle East, Southeast Asia, the US, Latin America, Africa, and Asia, with cumulative sales exceeding 22 million threads over eight or more years of international operations. Its go-to-market is built around event-driven academic marketing: active participation in 10+ international aesthetic congresses (IMCAS, AMWC, Dubai Derma, COSMOPROF, etc.), KOL-led training webinars for physicians in Southeast Asia and the EU, hands-on workshops, and a multi-language web presence. Pricing is not publicly disclosed and is negotiated directly with distributors and clinics. Oreon is led by President Evan Oh, with Dr. Kang Safi and Dr. Jung JaeYun serving as Medical Advisors. Revenue is not publicly reported; the company has executed a 10-for-1 stock split effective March 31, 2025, with 101,950 total shares outstanding.

Name

Oreon Life Science Co. Ltd.

Legal name

OREON Life science co., Ltd.

Website

https://oreonglobal.com

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Oreon Life Science is a privately held South Korean medical aesthetics manufacturer founded in 2000 that develops and globally distributes thread lifts, hyaluronic acid and PLLA fillers, mesotherapy, cannulas, cosmeceuticals, and toxin products through exclusive regional distributors in 70+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

Seoul (Songpa-gu)

HQ country

South Korea

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Aesthetic Product Sales: ORECON Life Science generates revenue primarily through the sale of its proprietary medical aesthetic product portfolio, including thread lifts (Rainbow Thread), dermal fillers (AESSOA, re:on, aesPlla), micro-cannulas, mesotherapy solutions (RE:ONNE), cosmeceutical mask packs (DN64, Chitosan, E.G.F), toxin products (reonox), and Lidocaine Cream. Products are sold to physicians and clinics through a global distributor network across over 70 countries.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Oreon Life Science Co. Ltd. is a South Korea-based medical aesthetics manufacturer founded in 2000. The company develops, manufactures, and globally distributes injectable aesthetic products including PDO/PLLA/PCLA lifting threads, hyaluronic acid (HA) dermal fillers, PLLA collagen stimulators, botulinum toxin, mesotherapy solutions, cannulas, and complementary skincare items for licensed physicians and clinics.

Product overview

Oreon Life Science Co. Ltd. is a Korean medical aesthetics company founded in 2000, offering a comprehensive product portfolio centered on minimally invasive aesthetic treatments. The portfolio is organized into five core product lines: (1) Rainbow Thread — thread lifting products (PDO, PLLA, PCLA) with multiple configurations including Mono, Screw, Twin, 3D/6D Cog, Heart Lifting, Dual Arm, and specialized variants for face and body lifting; (2) Dermal Fillers — two distinct lines: AESSOA (monophasic HA with lidocaine, 24mg/ml, in SHINE/GLOBAL/DEEP/ULTRA variants) and re:on (biphasic HA at 20mg/ml, in GLOBAL/DEEP/ULTRA variants), each with matching cannula systems; (3) aesPlla® — PLLA collagen stimulator filler; (4) RE:ONNE — mesotherapy solution with patented peptides and multi growth factors for skin and scalp; and (5) Cosmeceuticals — mask packs (DN64 bio-cellulose, Chitosan, E.G.F.) and Lidocaine Cream. The company operates two manufacturing plants (Osong since 2013, Seongnam since 2019) and serves over 70 countries globally with CE, ISO 13485, ISO 9001, GMP, and Korean FDA certifications.

Differentiator

Problem solved

Functional benefit

Brands

• RAINBOW Thread: Premium lifting treatment threads for non-surgical face and body lifting, contouring, and rejuvenation using PDO, PLLA, and PCLA materials.
• AESSOA
• re:on
• RE:ONNE
• aesPlla
• DN64
• Chitosan Mask Pack
• E.G.F Repair Hydrogel Mask
• reonox
• Lidocaine Cream

Products and services

• Rainbow Thread PDO, PLLA, and PCLA absorbable thread products used by aesthetic physicians for non-surgical facial lifting and skin tightening procedures.
• AESSOA Monophasic hyaluronic acid (HA) dermal filler for facial volume restoration and wrinkle correction, sold to licensed medical practitioners.
• re:on Biphasic hyaluronic acid dermal filler for facial contouring and aesthetic volume enhancement, supplied to clinics and medical professionals.
• aesPlla Poly-L-lactic acid (PLLA) collagen stimulator injectable designed to gradually restore facial volume and stimulate collagen production in patients.
• RE:ONNE Mesotherapy solution used by aesthetic practitioners for skin rejuvenation and revitalization treatments.
• reonox Botulinum toxin injectable for cosmetic wrinkle reduction, supplied to licensed practitioners for aesthetic procedures.
• Cannulas Blunt-tip injection cannulas designed for safe delivery of fillers and other injectable aesthetic products.
• Mask Packs (DN64, Chitosan, E.G.F) Post-treatment skincare mask packs including DN64, Chitosan, and E.G.F variants intended for use following aesthetic procedures.
• Lidocaine Cream Topical anesthetic cream used prior to injectable aesthetic procedures to reduce patient discomfort.

Quantifiable outcome

• Over 22 million threads sold globally
• +2 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Southeast Asian Distribution PartnerscoreChannel Partner/ Reseller/ DistributorORECON Life Science partners with exclusive distributors in Southeast Asian markets. The company conducted a webinar for Southeast Asian partners and their physicians covering Rainbow thread lifting techniques and product education. The webinar was delivered by KOL Dr. Jung JaeYun and received positive response from attendees.
• European Union Physician NetworkcoreChannel Partner/ Reseller/ DistributorORECON Life Science conducted webinars for physicians across 5 EU countries as part of its expansion into the European Union market. The webinars covered thread lifting techniques and Dynamic Facial Anatomy education, building the company's EU physician network through academic engagement.
• Global KOLs (Key Opinion Leaders)coreStrategic or Co-development PartnerORECON Life Science works with local and global Key Opinion Leaders including Dr. Jung JaeYun (Mielle Clinic Network) and Dr. Kang Safi (Seoul Face 21 Hospital) who serve as Medical Advisors. KOLs provide detailed lectures on Rainbow Thread effectiveness, conduct hands-on training workshops, and contribute to product education programs.

Scale indicators5 records

Recent moves10 records

Expansion highlights6 records

Broad incumbents

• Galderma: Global aesthetics market leader (Restylane, Sculptra, Dysport) with operations across fillers, biostimulators, and toxins. Competes with Oreon across virtually every product category but is a broader incumbent rather than a focused specialist; Oreon's threads and Korean aesthetic positioning sit adjacent to Galderma's portfolio.
• Merz Aesthetics: Global aesthetics player (Belotero Balance, Radiesse, Xeomin) competing with Oreon's HA filler and PLLA biostimulator lines. Larger, more diversified incumbent with deeper clinical data and US market presence — Oreon competes primarily outside Merz's core markets.
• AbbVie / Allergan Aesthetics: Global aesthetics leader (Botox, Juvederm, CoolSculpting) under AbbVie. Represents the gold-standard competitive backdrop for Oreon's toxin (reonox) and filler launches; Oreon's KOL network and pricing flexibility differentiate it from Allergan's premium positioning but cannot match Allergan's brand equity.

Direct peers

• Daewoong Pharmaceutical: Korean pharmaceutical company with a major aesthetics franchise (Nabota botulinum toxin, dermal fillers). Directly comparable to Oreon as a Korean-headquartered aesthetics manufacturer pursuing international CE/FDA approvals and competing for the same physician customers globally.
• Medytox: Korean aesthetics company best known for Meditoxin (a botulinum toxin competing with Botox) and a growing HA filler portfolio. Direct Korean peer to Oreon with similar global expansion ambitions via distributors and overlapping physician customer base in Asia and emerging markets.
• Hugel: Korean medical aesthetics company offering botulinum toxin (Botulax), HA fillers, and skin boosters with global distribution. Hugel is the most direct Korean peer to Oreon — overlapping product categories (toxins, fillers, thread-adjacent aesthetics) and competing for the same Korean KOL base and international distributor network. Listed on KOSDAQ.
• LG Chem (LG Aesthetics / Yvoire): South Korean conglomerate division producing Yvoire HA dermal fillers for the global aesthetics market. Competes head-to-head with Oreon's AESSOA and re:on filler lines for physician accounts, particularly in Asia, Middle East, and CIS markets where Oreon has strong distribution.
• Sinclair Pharma: UK-based aesthetics company specializing in thread lifts (Silhouette Soft/InstaLift) and PLLA biostimulators (Ellansé). The closest direct peer to Oreon's Rainbow Thread and aesPlla product lines, serving the same physician customer base for facial lifting and collagen stimulation procedures.
• Teoxane: Swiss aesthetics company specializing in HA dermal fillers (Teosyal range). Historically a Korean distribution partner of Oreon (Teosyal launched in Korea 2006); now a direct competitor in the international HA filler market with overlapping physician customers.

Emerging players

• Croma-Pharma: Austrian aesthetics company producing HA fillers (Princess range), PRP systems, and thread lifts. Comparable in size and product breadth to Oreon, with similar European-centric distribution and physician training model — useful comparable for Oreon's CE-certified thread and filler strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCAytQ0e21nNAOsy7Pm-GuIQ
• Facebookfacebook.com/OREON.AESSOA.Rainbow
• Instagraminstagram.com/oreon_lifescience
• LinkedInlinkedin.com/company/oreon-life-science

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oreon Life Science Co. Ltd.